Search Clinical Trials in the EU

Duration

Visits

Confirmation phase (III)

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

821-840 of 1,307 trials

Lung Fibrosis: Nerandomilast Study

We are testing whether nerandomilast can improve lung function in people with lung fibrosis related to rheumatic diseases. The study will also look at safety, including the risk of infections.

Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational MedicinesPulmonologyRheumatology

Tocolysis for Preterm Premature Rupture of Membranes

We are studying whether a short-term treatment can help pregnant individuals with PPROM before 34 weeks of gestation. The goal is to see if it reduces complications for mothers and their babies.

Complicated ChildbirthConfirmation phase (III)Standard MedicinesGynecology and Obstetrics

Kidney Health: CO2 Injection in Vascular Procedures

We are testing a new method using Carbon Dioxide instead of traditional contrast media for patients at risk of kidney injury during vascular interventions. This study aims to see if it can help prevent serious kidney problems after the procedure.

Peripheral Arterial Disease (PAD)>2 yearsConfirmation phase (III)≤5 visits No Placebo Investigational Medicines Partially RemoteCardiologyNephrology

Primary Adrenal Insufficiency: Plenadren vs. Cortisone

We are investigating how treatment with Plenadren affects quality of life compared to cortisone in individuals aged 16-80 newly diagnosed with primary adrenal insufficiency.

Primary Adrenal Insufficiency>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteEndocrinology

Cirrhosis Due to NASH/MASH: Efruxifermin Study

We are testing a new medication, Efruxifermin, for people with compensated cirrhosis from NASH/MASH. The study aims to see if it improves liver health and reduces related health risks compared to a placebo.

Non-Alcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH)>2 yearsConfirmation phase (III)Investigational Medicines Cost ReimbursementEndocrinologyHepatology

Acute Heart Failure: Intra-Abdominal Pressure and Ultrasound Study

We are exploring whether using intra-abdominal pressure and ultrasound can improve diuretic treatment for patients with acute heart failure. This study aims to see if these methods help reduce congestion and improve recovery compared to standard treatment.

Acute Heart Failure>2 yearsConfirmation phase (III)≤5 visits No Placebo Standard MedicinesCardiologyInternal Medicine

Multiple Sclerosis: ABP 692 vs. Ocrevus

We are comparing a new treatment called ABP 692 with Ocrevus for people with relapsing-remitting multiple sclerosis. The goal is to see how they differ in effectiveness and safety.

Relapsing-Remitting Multiple Sclerosis>2 yearsConfirmation phase (III)16-20 visits No Placebo Investigational Medicines Cost ReimbursementNeurology

Advanced Breast Cancer: PF-07220060 with Letrozole

We are studying a new medicine, PF-07220060, combined with letrozole for adults with HR-positive, HER2-negative advanced breast cancer. This trial compares its effectiveness to standard treatments in patients who haven't had prior systemic therapy.

Advanced/Metastatic Breast CancerConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Advanced Breast Cancer: Elacestrant and Everolimus Study

We are studying a combination of elacestrant and everolimus for patients with advanced breast cancer that has specific mutations. The goal is to see if this treatment helps delay cancer progression compared to a placebo.

Advanced Estrogen Receptor-Positive Breast Cancer1-2 yearsConfirmation phase (III)Investigational MedicinesEndocrinologyOncology

Menstrual Migraine: Atogepant Study

We are testing Atogepant to see if it can help prevent menstrual migraines. The study will also look at its safety and how well people tolerate the treatment.

Menstrual Migraine6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementGynecology and ObstetricsNeurology

Sepsis Treatment: New Antibiotic Dosing Strategy

We are testing a new way to dose beta-lactam antibiotics for critically ill patients with sepsis. The goal is to see if this improves their recovery in the ICU.

Sepsis1-2 yearsConfirmation phase (III)Monitoring phase (IV)No Placebo Standard MedicinesInfectious DiseasesInternal MedicinePulmonology

Lung Cancer: Sacituzumab and Zimberelimab Treatment

We are studying a combination of two medications for patients with non-small cell lung cancer who have had surgery but are not disease-free. The goal is to see if this treatment can help prevent cancer from returning.

Resectable Non-small Cell Lung CancerConfirmation phase (III)No Placebo Investigational MedicinesOncologyPulmonology

Ovarian Cancer: Continued Treatment with Olaparib

We are providing ongoing treatment with Olaparib for patients who have benefited from it in a previous study. This trial focuses on monitoring safety while allowing continued access to the medication.

Ovarian CancerBreast CancerProstate Cancer>2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

ENPP1 Deficiency: INZ-701 Study

We are investigating whether the drug INZ-701 can help infants with ENPP1 deficiency by improving survival and preventing heart and respiratory problems. The study aims to see if it can also support physical growth and reduce artery issues.

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteCardiologyPediatrics

Non-Small Cell Lung Cancer: Acasunlimab and Pembrolizumab Study

We are evaluating a new combination treatment for patients with advanced non-small cell lung cancer who have already received other therapies. The goal is to see if this combination works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Ulcerative Colitis: RO7790121 Treatment Study

We are studying a new treatment for people with moderately to severely active ulcerative colitis to see if it can help induce remission. The trial will also assess its safety and impact on symptoms and quality of life.

Ulcerative ColitisConfirmation phase (III)Post-Trial Drug Access Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Major Depression: Samyr® Tablet Study

We are investigating whether Samyr® tablets can improve symptoms in patients with major depressive disorder who are not fully responding to their current treatment. The study compares Samyr® to a placebo to assess its effectiveness and safety.

Major Depression Disorder≤3 monthsConfirmation phase (III)6-10 visits Investigational Medicines Partially RemotePsychiatry

Major Depression: Samyr Injection Study

We are testing whether Samyr, an injectable treatment, can improve symptoms in people with major depression who are not responding well to their current antidepressants. This study compares Samyr to a placebo to assess its effectiveness and safety.

Major Depression Disorder≤3 monthsConfirmation phase (III)11-15 visits Investigational MedicinesPsychiatry

Invasive Aspergillosis: Olorofim vs. AmBisome®

We are studying a new treatment called olorofim for patients with invasive aspergillosis to see if it works better and is safer than the standard treatment, AmBisome®. This trial will also look at how these treatments affect patients' quality of life.

Invasive Fungal Infection3-6 monthsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementInfectious DiseasesInternal Medicine

Bipolar Mania: Lumateperone Study

We are evaluating the safety and effectiveness of lumateperone for treating manic episodes in patients with bipolar I disorder. This study compares the medication to a placebo to see how well it works.

Bipolar Disorder≤3 monthsConfirmation phase (III)≤5 visits Investigational Medicines Cost ReimbursementPsychiatry

Search Clinical Trials in the European Union